T-CELL PROLYMPHOCYTIC LEUKEMIA
Clinical trials for T-CELL PROLYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new T-CELL PROLYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for T-CELL PROLYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests the safety of combining two drugs, ruxolitinib and duvelisib, in people with T- or NK-cell lymphoma that has come back or not responded to prior treatments. About 70 participants will receive the drugs to find the best dose and see if the combination …
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 01, 2026 13:14 UTC
-
New hope: drug may stop lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…
Matched conditions: T-CELL PROLYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC